By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Bridge to New Markets.

Boehringer Ingelheim acquires Tyrolean biotech company ViraTherapeutics

© Boehringer Ingelheim

The startup which was spun off from the University of Innsbruck in 2013 focuses on the development of oncolytic viral therapies serving as an immunotherapy in the fight against cancer. "The acquisition strengthens Boehringer Ingelheim's commitment to research and development of viral-based immuno-oncology treatment options for cancer patients", says Boehringer Ingelheim.

The company has already been involved with ViraTherapeutics since 2016 together with EMBL Ventures. ViraTherapeutics will become a separate unit of Boehringer Ingelheim's research organization. 19 researchers are currently employed at the facility in Innsbruck. Up until now the shares in ViraTherapeutics were held by Boehringer Ingelheim Venture Fonds, which acquires stakes in innovative startups in the pharmaceutical sector. 22 young companies are currently in the Boehringer Ingelheim portfolio. Boehringer Ingelheim is very strongly committed to both research and production in Austria. The entire cancer research of the company is bundled in Vienna. At present the Group is investing about EUR 700 million in a new biotech production plant in Vienna.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Meet us @ The Grow by SalsUp

    20.04.2021/ 16:30 Uhr - 19:00 Uhr, Wien, Österreich

  • Ukrainian-Austrian Business Forum

    27.4.2021/ 14.00 (CET) , Online Conference

Austria Map

Find the perfect location for your company

Reliability and expertise in the country and in the company are the convincing factors in selecting a business location. We can be justifiably proud but can still become even more attractive. This is something Austria should increasingly work on in the future!

Pfizer

Logo
More testimonials

news from the business location Austria

Austrians conduct research in New York on low-priced vaccine

Two Austrians are conducting research in New York on a vaccine against the coronavirus which is designed to be available at a particularly low price and also be easy to dispense.

Shared Mobility in Austria!

"A green planet with mobility from everyone, for everyone" has continuously been the motto of GO Sharing.

More news All blog posts